Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local cooling to reduce pain and bruising from subcutaneous enoxaparin injections in cardiovascular patients
IRCT201602029014N92Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enoxaparin in cardiac morbidity and venous thromboembolism (VTE) (3 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Pain severity at injection site and Extent of bruise at injection site. Started Feb 2016; status: completed.
02
Drugs
enoxaparin
03
Conditions
cardiac morbidityvenous thromboembolism (VTE)
Beyond the preview
Go deeper on IRCT201602029014N92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201602029014N92.